Navigation Links
AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
Date:12/7/2009

QUEBEC CITY, Dec. 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

Study Z-036 did not reach its primary endpoint. There were no clear differences in overall efficacy, with all 3 groups (including placebo) showing an improvement in International Prostate Symptom Score (IPSS) of approximately 6 points that was maintained throughout the 52 weeks. There was observation of an improvement in uroflow, both maximum and mean, and in residual volume in all treatment groups. These favorable changes are reflected in an overall improvement in Quality of Life measures. Cetrorelix was well tolerated, there were no relevant differences to placebo with regard to both clinical adverse events or changes in laboratory parameters with the exception of the anticipated hormonal changes.

Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, "We are obviously disappointed by the failure of study Z-036 to reach its efficacy endpoint. Despite the disappointment, we would like to thank the investigators and all those involved in this project for their dedicated work. We will now focus our development efforts on our late-stage oncology compounds perifosine, our oral PI3K/AKT inhibitor and AEZS-108, our targeted doxorubicin conjugate, as well as our oral ghrelin agonist AEZS-130 in endocrinology."

About study Z-036

The multi-center efficacy trial Z-036 was conducted in 39 sites in 10 European countries, under the supervision of lead investigator, Prof. Frans MJ Debruyne, M.D., Director of the Andros Mannenkliniek in Arnhem, The Netherlands. Patients entered a 1- to 4
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... 2014 A novel robotic system that ... is currently being tested as part of a biomedical ... Boston with the aim of determining if the robot, ... cancer biopsies faster, more accurate, less costly, and less ... the potential to deliver prostate cancer therapies with greater ...
(Date:9/18/2014)... Station, Texas (PRWEB) September 18, 2014 ... System Chancellor John Sharp, Texas A&M Health Science ... the U.S. Department of Health and Human Services ... today dedicated a national pandemic influenza vaccine manufacturing ... serve as an anchor for the Texas A&M ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global N-acetylcysteine Industry Report 2014 2
... Maxygen, Inc. (Nasdaq: MAXY ) that it has ... also known as R7025.,MAXY-alpha is a novel interferon-alpha for ... and is licensed to Roche. Preliminary observations from ... the pharmacodynamic and pharmacokinetic effects of,MAXY-alpha occurred in the ...
... ITMN ) today announced the pricing of its ... stock at a price to the,public of $19.50 per ... purchase up to an additional 525,000 shares of common,stock. ... sold by InterMune. Goldman, Sachs & Co. is ...
... YORK, Sept. 21 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ... to,the Company,s Board of Directors. Mr. Tarnok, 53, ... with extensive pharmaceutical industry experience in a wide,range of ... career at,Pfizer Inc., which he joined in 1989 as ...
Cached Biology Technology:Maxygen Announces Hold on MAXY-alpha Development Program 2Maxygen Announces Hold on MAXY-alpha Development Program 3InterMune Announces Pricing of $68 Million Public Offering of Common Stock 2Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors 2
(Date:9/18/2014)... and nitrogen comprise all spheres of our planet. ... caused imbalances and perturbations that resulted in increases ... result in climate changes which influence the complex ... atmosphere. Understanding these feedback mechanisms has become an ... during the past three decades. , In parallel, ...
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/18/2014)... probably the ultimate form of camouflage: you don,t just ... strategy is not as uncommon as you might think. ... USA, explains that the larval life stages of many ... of the anatomy that most creatures cannot make transparent. ... to shield each individual eye unit with an opaque ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2
... New evidence that chemical contaminants are finding their way ... deep-sea squids and octopods, including the strange-looking "vampire squid". ... other predators. In a study to be published ... Vecchione of NOAA Fisheries, National Systematics Laboratory and colleagues ...
... N.Y. A new book, Grounds ... of historic and modern buildings and the striking landscape that ... tree enthusiast Elizabeth L. Watson, who, together with her husband ... homes on the picturesque grounds of CSHL for almost four ...
... The Institute for Genomics and Systems Biology (IGSB), a ... National Laboratory and the University of Chicago, has acquired two ... more quickly and broadly. "Sequencing used to be ... fairway, but not the rough," said IGSB Director Kevin White. ...
Cached Biology News:Persistent man-made chemical pollutants found in deep-sea octopods and squids 2Persistent man-made chemical pollutants found in deep-sea octopods and squids 3Argonne-University of Chicago joint venture bolsters genomic sequencing capabilities 2
... The EC570-90 is a compact, lightweight, high ... 500 volts or 2500 milliamps. It is an ... RNA submarine gels. It is also ideal for ... time can be set to automatically end a ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
QCPN...
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Biology Products: